Art. -Nr.: HY-14248

Letrozole

(Synonyms: CGS 20267)

21 Cited Publications

Kundenbewertung

Based on 21 publication(s) in Google Scholar

Letrozole (CGS 20267) is a potent, selective, reversible and orally active non-steroidal inhibitor of aromatase, with an IC₅₀ of 11.5 nM. Letrozole selective inhibits estrogen biosynthesis, and can be used for the research of breast cancer.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.95%
CAS. Nr.: 112809-51-5
Formel: C₁₇H₁₁N₅
Molecular Weight:285.30

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Letrozole Chemical Structure

CAS. Nr.: 112809-51-5

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (21)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

Aromatase

Alle Cytochrome P450 Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
ARO	IC₅₀	1.8 nM Compound: 1; LTZ	Inhibition of human recombinant aromatase using ARO as substrate Inhibition of human recombinant aromatase using ARO as substrate	[PMID: 37037140]
BT-549	GI₅₀	0.89 μM Compound: Letrozole	Growth inhibition of human BT549 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human BT549 cells after 48 hrs by sulforhodamine B assay	[PMID: 20950898]
HeLa	GI₅₀	>100 μM Compound: Letrozole	Growth inhibition of non-estrogen-sensitive human HeLa cells after 72 hrs by MTT assay Growth inhibition of non-estrogen-sensitive human HeLa cells after 72 hrs by MTT assay	[PMID: 24025069]
Hs-578T	GI₅₀	2.17 μM Compound: Letrozole	Growth inhibition of human Hs 578T cells after 48 hrs by sulforhodamine B assay Growth inhibition of human Hs 578T cells after 48 hrs by sulforhodamine B assay	[PMID: 20950898]
HT-29	GI₅₀	>100 μM Compound: Letrozole	Growth inhibition of non-estrogen-sensitive human HT-29 cells after 72 hrs by MTT assay Growth inhibition of non-estrogen-sensitive human HT-29 cells after 72 hrs by MTT assay	[PMID: 24025069]
IGROV-1	GI₅₀	>100 μM Compound: Letrozole	Growth inhibition of estrogen-sensitive human IGROV1 cells after 72 hrs by MTT assay Growth inhibition of estrogen-sensitive human IGROV1 cells after 72 hrs by MTT assay	[PMID: 24025069]
IGROV-1	GI₅₀	0.095 μM Compound: Letrozole	Growth inhibition of human IGROV1 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human IGROV1 cells after 48 hrs by sulforhodamine B assay	[PMID: 20950898]
JEG-3	IC₅₀	0.89 nM Compound: letrozole	Inhibition of aromatase in human JEG3 cells by scintillation spectrometry Inhibition of aromatase in human JEG3 cells by scintillation spectrometry	[PMID: 20148564]
JEG-3	IC₅₀	0.89 nM Compound: 111	Inhibition of aromatase (unknown origin) expressed in JEG-3 cells Inhibition of aromatase (unknown origin) expressed in JEG-3 cells	[PMID: 25992880]
JEG-3	IC₅₀	0.89 nM Compound: letrozole	Inhibition of aromatase activity in human JEG3 cells Inhibition of aromatase activity in human JEG3 cells	[PMID: 18590272]
Jurkat	GI₅₀	>100 μM Compound: Letrozole	Growth inhibition of non-estrogen-sensitive human Jurkat cells after 72 hrs by MTT assay Growth inhibition of non-estrogen-sensitive human Jurkat cells after 72 hrs by MTT assay	[PMID: 24025069]
MCF-10A	IC₅₀	>10 μM Compound: Letrozole	Antiproliferative activity against human MCF-10A cells assessed as reduction in cell viability after 72 hrs by cell counter method Antiproliferative activity against human MCF-10A cells assessed as reduction in cell viability after 72 hrs by cell counter method	[PMID: 34364162]
MCF-10A	IC₅₀	>100 μM Compound: 1; LTZ	Cytotoxicity against human MCF-10A cells incubated for 72 hrs by CCK8 assay Cytotoxicity against human MCF-10A cells incubated for 72 hrs by CCK8 assay	[PMID: 37037140]
MCF-10A	IC₅₀	>100 μM Compound: LTZ	Anti-proliferative activity against human MCF-10A cells incubated for 96 hrs by CCK8 assay Anti-proliferative activity against human MCF-10A cells incubated for 96 hrs by CCK8 assay	[PMID: 38809993]
MCF7	GI₅₀	>100 μM Compound: Letrozole	Growth inhibition of estrogen-sensitive human MCF7 cells after 72 hrs by MTT assay Growth inhibition of estrogen-sensitive human MCF7 cells after 72 hrs by MTT assay	[PMID: 24025069]
MCF7	GI₅₀	0.7 μM Compound: Letrozole	Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay	[PMID: 20950898]
MCF7	GI₅₀	4.1 μM Compound: LTZ	Growth inhibition of human MCF7 cells incubated for 72 hrs by cell counting based method Growth inhibition of human MCF7 cells incubated for 72 hrs by cell counting based method	[PMID: 30822713]
MCF7	IC₅₀	>100 μM Compound: 1; LTZ	Antiproliferative activity against human MCF7 cells incubated for 72 hrs by CCK8 assay Antiproliferative activity against human MCF7 cells incubated for 72 hrs by CCK8 assay	[PMID: 37037140]
MCF7	IC₅₀	>100 μM Compound: LTZ	Antiproliferative activity against human resistant MCF7 cells harboring EGFR assessed as cell viability incubated for 96 hrs by CCK8 assay Antiproliferative activity against human resistant MCF7 cells harboring EGFR assessed as cell viability incubated for 96 hrs by CCK8 assay	[PMID: 38809993]
MCF7	IC₅₀	>100 μM Compound: LTZ	Antiproliferative activity against human resistant MCF7 cells harboring ERalpha D538G mutant at LBD assessed as cell viability incubated for 96 hrs by CCK8 assay Antiproliferative activity against human resistant MCF7 cells harboring ERalpha D538G mutant at LBD assessed as cell viability incubated for 96 hrs by CCK8 assay	[PMID: 38809993]
MCF7	IC₅₀	>100 μM Compound: LTZ	Antiproliferative activity against human resistant MCF7 cells harboring ERalpha Y537S mutant at LBD assessed as cell viability incubated for 96 hrs by CCK8 assay Antiproliferative activity against human resistant MCF7 cells harboring ERalpha Y537S mutant at LBD assessed as cell viability incubated for 96 hrs by CCK8 assay	[PMID: 38809993]
MCF7	IC₅₀	20 nM Compound: Letrozole	Cytotoxicity against human MCF7 cells after 24 to 96 hrs Cytotoxicity against human MCF7 cells after 24 to 96 hrs	[PMID: 24345481]
MCF7	IC₅₀	4.1 μM Compound: Letrozole	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by cell counter method Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by cell counter method	[PMID: 34364162]
MCF7	IC₅₀	4.73 μM Compound: Letrozole	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 29202405]
MCF7	IC₅₀	7 nM Compound: Letrozole	Cytotoxicity against estrogen-dependent human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against estrogen-dependent human MCF7 cells after 72 hrs by MTT assay	[PMID: 24345481]
MCF7	IC₅₀	8.8 μM Compound: LTZ	Anti-proliferative activity against ERalpha positive human MCF7 cells incubated for 96 hrs by CCK8 assay Anti-proliferative activity against ERalpha positive human MCF7 cells incubated for 96 hrs by CCK8 assay	[PMID: 38809993]
MDA-MB-231	GI₅₀	0.15 μM Compound: Letrozole	Growth inhibition of human MDA-MB-231cells after 48 hrs by sulforhodamine B assay Growth inhibition of human MDA-MB-231cells after 48 hrs by sulforhodamine B assay	[PMID: 20950898]
MDA-MB-231	GI₅₀	10 μM Compound: LTZ	Growth inhibition of human MDA-MB-231 cells incubated for 72 hrs by cell counting based method Growth inhibition of human MDA-MB-231 cells incubated for 72 hrs by cell counting based method	[PMID: 30822713]
MDA-MB-231	GI₅₀	34 μM Compound: LTZ	Growth inhibition of human ER-negative MDA-MB-231 cells incubated for 72 hrs by cell counter method Growth inhibition of human ER-negative MDA-MB-231 cells incubated for 72 hrs by cell counter method	[PMID: 32435378]
MDA-MB-435	GI₅₀	0.067 μM Compound: Letrozole	Growth inhibition of human MDA-MB-435 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human MDA-MB-435 cells after 48 hrs by sulforhodamine B assay	[PMID: 20950898]
MDA-N	GI₅₀	1.61 μM Compound: Letrozole	Growth inhibition of human MDA-N cells after 48 hrs by sulforhodamine B assay Growth inhibition of human MDA-N cells after 48 hrs by sulforhodamine B assay	[PMID: 20950898]
NCI/ADR-RES	GI₅₀	1.16 μM Compound: Letrozole	Growth inhibition of human NCI/ADR-RES cells after 48 hrs by sulforhodamine B assay Growth inhibition of human NCI/ADR-RES cells after 48 hrs by sulforhodamine B assay	[PMID: 20950898]
NCI-H295R	GI₅₀	>100 μM Compound: Letrozole	Growth inhibition of estrogen-sensitive human NCI-H295R cells after 72 hrs by MTT assay Growth inhibition of estrogen-sensitive human NCI-H295R cells after 72 hrs by MTT assay	[PMID: 24025069]
OVCAR-3	GI₅₀	>100 μM Compound: Letrozole	Growth inhibition of estrogen-sensitive human OVCAR3 cells after 72 hrs by MTT assay Growth inhibition of estrogen-sensitive human OVCAR3 cells after 72 hrs by MTT assay	[PMID: 24025069]
OVCAR-3	GI₅₀	5.87 μM Compound: Letrozole	Growth inhibition of human OVCAR3 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human OVCAR3 cells after 48 hrs by sulforhodamine B assay	[PMID: 20950898]
OVCAR-4	GI₅₀	0.88 μM Compound: Letrozole	Growth inhibition of human OVCAR4 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human OVCAR4 cells after 48 hrs by sulforhodamine B assay	[PMID: 20950898]
OVCAR-5	GI₅₀	1.62 μM Compound: Letrozole	Growth inhibition of human OVCAR5 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human OVCAR5 cells after 48 hrs by sulforhodamine B assay	[PMID: 20950898]
OVCAR-8	GI₅₀	4.5 μM Compound: Letrozole	Growth inhibition of human OVCAR8 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human OVCAR8 cells after 48 hrs by sulforhodamine B assay	[PMID: 20950898]
RS4-11	GI₅₀	>100 μM Compound: Letrozole	Growth inhibition of non-estrogen-sensitive human RS4:11 cells after 72 hrs by MTT assay Growth inhibition of non-estrogen-sensitive human RS4:11 cells after 72 hrs by MTT assay	[PMID: 24025069]
SEM	GI₅₀	>100 μM Compound: Letrozole	Growth inhibition of non-estrogen-sensitive human SEM cells after 72 hrs by MTT assay Growth inhibition of non-estrogen-sensitive human SEM cells after 72 hrs by MTT assay	[PMID: 24025069]
SK-OV-3	GI₅₀	1.09 μM Compound: Letrozole	Growth inhibition of human SKOV3 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human SKOV3 cells after 48 hrs by sulforhodamine B assay	[PMID: 20950898]
T47D	GI₅₀	0.44 μM Compound: Letrozole	Growth inhibition of human T47D cells after 48 hrs by sulforhodamine B assay Growth inhibition of human T47D cells after 48 hrs by sulforhodamine B assay	[PMID: 20950898]
T47D	IC₅₀	29.5 μM Compound: Letrozole	Inhibition of aromatase activity in human T47D cells after 24 hrs Inhibition of aromatase activity in human T47D cells after 24 hrs	[PMID: 27770735]

In Vitro

Letrozole (0.1-100 nM; 24-96 h) significantly inhibits growth of the MCF-7 epithelial breast cancer cells in a dose- and time-dependent manner^[2].
Letrozole (10 nM) significantly suppresses the stimulatory effects of testosterone on MCF-7 cell proliferation^[2].
Letrozole (10 nM; 24-48 h) suppresses the levels of secreted metalloproteinases (MMP‐2 and MMP‐9) in MCF-7 cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:

MCF-7 cells
Concentration:

0.1, 1, 10, 100 nM
Incubation Time:

24, 48, 96 hours
Result:

Inhibited cells growth in a dose- and time-dependent manner.

In Vivo

Letrozole (3-300 μg/kg; oral gavage once daily for 6 weeks) exhibits anti-tumor effects in rats^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Adult female rats bearing mammary tumors^[3]
Dosage:

3, 10, 30, 100, 300 μg/kg
Administration:

Oral gavage once daily for 6 weeks
Result:

Induced complete regression of mammary tumors, with an ED₅₀ of 10-30 μg/kg/day.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 112809-51-5
Appearance Solid
Molecular Weight 285.30
Formel C₁₇H₁₁N₅
Color White to off-white
SMILES

N#CC1=CC=C(C(N2C=NC=N2)C3=CC=C(C#N)C=C3)C=C1
Synonyms

CGS 20267
Structure Classification
- Alkaloids
- Other Alkaloids
Initial Source
- Plants
- Compositae
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (21)

All Cell Proliferation/Viability AssayCell Imaging/StainingRT-PCRIn Vivo ImagingIHCIFWB

Sort by:

Journal Impact Factor

Nat Commun

MeCP2 Governs maternal hyperandrogenism-induced cortical defects and behavioral alterations via noncanonical AR-dependent regulation of Mef2c. [Abstract]

2026 May 13;17(1):4225. PMID: 42129177
Nucleic Acids Res

An H3K4me3 reader, BAP18 as an adaptor of COMPASS-like core subunits co-activates ERα action and associates with the sensitivity of antiestrogen in breast cancer. [Abstract]

2020 Nov 4;48(19):10768-10784. PMID: 32986841

Letrozole purchased from MedChemExpress. Usage Cited in: Nucleic Acids Res. 2020 Nov 4;48(19):10768-10784. [Abstract]

Letrozole (10-50 nM; 14 days). The influence of BAP18 on endocrine drug sensitivity in T47D cells. T47D cells were pre-transfected with FLAG-tagged PcDNA3 plasmids (Parental) and BAP18 expression plasmids (oeBAP18). Cultured in different concentrations of three kinds of endocrine drugs for 14 days, cells in wells were stained by R250 and photographs represented one of three independent experiments.
Cell Death Differ

BAP18 facilitates CTCF-mediated chromatin accessible to regulate enhancer activity in breast cancer. [Abstract]

2023 May;30(5):1260-1278. PMID: 36828916

Letrozole purchased from MedChemExpress. Usage Cited in: Cell Death Differ. 2023 May;30(5):1260-1278. [Abstract]

Letrozole (10^-9-10^-1 M; 4 weeks). The IC50 experiment revealed that BAP18 deletion dramatically lowered the half-death concentration of Letrozole in MCF7 cells. Cells were treated with different concentrations of Letrozole for four weeks before counting the number of cells in each concentration group using cell counts.
Cancer Lett

Aromatase-induced endogenous estrogen promotes tumour metastasis through estrogen receptor-α/matrix metalloproteinase 12 axis activation in castration-resistant prostate cancer. [Abstract]

2019 Dec 28;467:72-84. PMID: 31499120
J Ethnopharmacol

Yangjing Zhongyu decoction facilitates mitochondrial activity, estrogenesis, and energy metabolism in H2O2-induced human granulosa cell line KGN. [Abstract]

2022 Sep 15:295:115398. PMID: 35605921
Ecotoxicol Environ Saf

Global expression response of genes in sex-undifferentiated Nile tilapia gonads after exposure to trace letrozole. [Abstract]

2021 Jul 1:217:112255. PMID: 33915448

Letrozole purchased from MedChemExpress. Usage Cited in: Ecotoxicol Environ Saf. 2021 Jul 1:217:112255. [Abstract]

PC3 cells were treated with 50 nM Letrozole for 0 h, 24 h, 48 h and 72 h, and the mRNA expression level of MMP12 was assayed by RT-PCR.

Letrozole purchased from MedChemExpress. Usage Cited in: Ecotoxicol Environ Saf. 2021 Jul 1:217:112255. [Abstract]

Letrozole (LE; 10 μg/day for 30 days; ip). Representative images of in vivo bioluminescent imaging for mice in the 5 groups using the IVIS imaging system.

Letrozole purchased from MedChemExpress. Usage Cited in: Ecotoxicol Environ Saf. 2021 Jul 1:217:112255. [Abstract]

Letrozole (LE; 10 μg/day for 30 days; ip). Representative images of the tumours immunostained with antibodies against aromatase, CD44 and MMP12.
Life Sci

Hyperoside mitigates PCOS-associated adipogenesis and insulin resistance by regulating NCOA2-mediated PPAR-γ ubiquitination and degradation. [Abstract]

2025 Jan 27:123417. PMID: 39880157
Cell Rep Methods

RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]

2023 Oct 23;3(10):100599. PMID: 37797618
Mol Cancer Res

Dual Inhibition of CDK4 and CDK2 via Targeting p27 Tyrosine Phosphorylation Induces a Potent and Durable Response in Breast Cancer Cells. [Abstract]

2018 Mar;16(3):361-377. PMID: 29330290
Aquaculture

2023 May 15.
Aquaculture

2020 Jul.
PLoS Genet

Two duplicated gsdf homeologs cooperatively regulate male differentiation by inhibiting cyp19a1a transcription in a hexaploid fish. [Abstract]

2022 Jun 29;18(6):e1010288. PMID: 35767574
J Pharm Biomed Anal

A hydrophobic deep eutectic solvent-based vortex-assisted liquid-liquid microextraction applied for doping control of aromatase inhibitors from equine urine. [Abstract]

2023 Sep 20:234:115583. PMID: 37494867
Genes (Basel)

Molecular Cloning and Expression Responses of Jarid2b to High-Temperature Treatment in Nile Tilapia (Oreochromis niloticus). [Abstract]

2022 Sep 25;13(10):1719. PMID: 36292604
Theriogenology

A novel therapeutic approach: The effect of letrozole-assisted synchronization on reproductive performance in suckling ewes during the non-breeding season. [Abstract]

2026 Feb 1:251:117751. PMID: 41223620
Reprod Sci

Network Pharmacology and In Vivo Validation Reveal Therapeutic Effects of Sutaehwan in Polycystic Ovary Syndrome by Modulating AMH-AMHR2 Signaling Pathway. [Abstract]

2025 Dec 13. PMID: 41389252
Drug Test Anal

High-throughput liquid chromatography tandem mass spectrometry assay as initial testing procedure for analysis of total urinary fraction. [Abstract]

2021 Feb;13(2):283-298. PMID: 32852861
Exp Ther Med

Effect of aromatase inhibitor letrozole on the proliferation of spermatogonia by regulating the MAPK pathway. [Abstract]

2018 Jun;15(6):5269-5274. PMID: 29805545

Letrozole purchased from MedChemExpress. Usage Cited in: Exp Ther Med. 2018 Jun;15(6):5269-5274. [Abstract]

Letrozole (100 nM; 72 h). Detection of the effects of Letrozole and the MAPK pathway on the proliferation of GC-1 spg cells by BrdU. MAPK, mitogen-activated protein kinase; spg, spermatogonia; BrdU, bromodeoxyuridine.

Letrozole purchased from MedChemExpress. Usage Cited in: Exp Ther Med. 2018 Jun;15(6):5269-5274. [Abstract]

Letrozole (100 nM; 72 h). Detection of the effect of Letrozole on the MAPK pathway by western blotting.
Syst Biol Reprod Med

Letrozole promotes the expression of integrin αvβ3 and HOXA10 in endometrium of endometriosis. [Abstract]

2022 Apr;68(2):121-128. PMID: 34962452
The Korea Journal of Herbology

2025.
SSRN

2024 Mar 16.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 50 mg/mL (175.25 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.5051 mL

17.5254 mL

35.0508 mL

5 mM

0.7010 mL

3.5051 mL

7.0102 mL

10 mM

0.3505 mL

1.7525 mL

3.5051 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (7.29 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (7.29 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (7.29 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (276 KB)
SDS (418 KB)
- English - EN (418 KB)
- Français - FR (418 KB)
- Deutsch - DE (418 KB)
- Norwegian - NO (418 KB)
- Español - ES (418 KB)
- Swedish - SV (418 KB)
- Italian - IT (418 KB)
- Korean - KR (418 KB)
- Portuguese - PT (418 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Bhatnagar AS, et, al. Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor. J Steroid Biochem Mol Biol. 1990 Dec 20;37(6):1021-7. [Content Brief]

[2]. Mitropoulou TN, et, al. Letrozole as a potent inhibitor of cell proliferation and expression of metalloproteinases (MMP-2 and MMP-9) by human epithelial breast cancer cells. Int J Cancer. 2003 Mar 20;104(2):155-60. [Content Brief]

[3]. Schieweck K, et, al. Anti-tumor and endocrine effects of non-steroidal aromatase inhibitors on estrogen-dependent rat mammary tumors. J Steroid Biochem Mol Biol. 1993 Mar;44(4-6):633-6. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.5051 mL	17.5254 mL	35.0508 mL	87.6271 mL
	5 mM	0.7010 mL	3.5051 mL	7.0102 mL	17.5254 mL
	10 mM	0.3505 mL	1.7525 mL	3.5051 mL	8.7627 mL
	15 mM	0.2337 mL	1.1684 mL	2.3367 mL	5.8418 mL
	20 mM	0.1753 mL	0.8763 mL	1.7525 mL	4.3814 mL
	25 mM	0.1402 mL	0.7010 mL	1.4020 mL	3.5051 mL
	30 mM	0.1168 mL	0.5842 mL	1.1684 mL	2.9209 mL
	40 mM	0.0876 mL	0.4381 mL	0.8763 mL	2.1907 mL
	50 mM	0.0701 mL	0.3505 mL	0.7010 mL	1.7525 mL
	60 mM	0.0584 mL	0.2921 mL	0.5842 mL	1.4605 mL
	80 mM	0.0438 mL	0.2191 mL	0.4381 mL	1.0953 mL
	100 mM	0.0351 mL	0.1753 mL	0.3505 mL	0.8763 mL

Keywords

Letrozole

21 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Letrozole

Anti-Infection Compound Library

Metabolism/Protease Compound Library

Natural Product Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Antioxidant Compound Library

Oxygen Sensing Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Alkaloids Library

Anti-Breast Cancer Compound Library

Drug-Induced Liver Injury (DILI) Compound Library

Targeted Therapy Drug Library

Mitochondria-Targeted Compound Library

Rare Diseases Drug Library

Anti-Cancer Natural Product Library

Plant-Sourced Natural Product Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Non-steroidal Anti-Inflammatory Compound Library

Off-patent Drug Library

Metabolic Enzyme Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Anti-Cancer Approved Drug Library

Mass Spectrometry Human Metabolite Library

Natural Product Diversity Scaffold Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Letrozole

Alle Cytochrome P450 Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (21)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Letrozole Related Classifications

HY-14248 Related Classifications